PK-PD modeling with the ACE-inhibitor imidapril in hypertensive patients.

被引：0
|
作者：
Harder, S
Thurmann, PA
Ungethum, W
机构：
[1] UNIV HOSP FRANKFURT, DEPT CLIN PHARMACOL, FRANKFURT, GERMANY
[2] MERCK KGAA, DARMSTADT, GERMANY
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1997年 / 61卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：PII88 / PII88
页数：1
相关论文
共 50 条
  • [41] Machine Learning and Artificial Intelligence in PK-PD Modeling: Fad, Friend, or Foe?
    Huang, Zhonghui
    Denti, Paolo
    Mistry, Hitesh
    Kloprogge, Frank
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (04) : 652 - 654
  • [42] Application of PK-PD Modeling in Understanding Bystander Effect for Antibody Drug Conjugates
    Singh, Aman P.
    Shah, Dhaval K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S27 - S28
  • [43] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING OF MIDAZOLAM-FLUMAZENIL INTERACTIONS
    FISET, P
    EGAN, T
    LEMMENS, H
    SHAFER, S
    STANSKI, D
    ANESTHESIOLOGY, 1993, 79 (3A) : A362 - A362
  • [44] The Pharmacokinetics/Pharmacodynamics of Resveratrol and Mechanism-based PK-PD Modeling Research
    Chen, Hui
    Liu, Xinxia
    Wan, Heng
    Zeng, Can
    FASEB JOURNAL, 2014, 28 (01):
  • [45] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING FOR METFORMIN IN HEALTHY VOLUNTEERS.
    Kim, Y.
    Cho, S.
    Lee, D.
    Son, H.
    Roh, H.
    Son, M.
    Heo, Y.
    Park, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S48
  • [46] Tubuloglomerular feedback and prolonged ACE-inhibitor treatment in the hypertensive fawn-hooded rat
    Verseput, GH
    Braam, B
    Provoost, AP
    Koomans, HA
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (04) : 893 - 899
  • [47] Comparative effects of ACE-inhibitor and calcium-antagonist in hypertensive patients after acute cardiogenic pulmonary edema
    Bracchetti, D
    Pavesi, PC
    Casella, G
    Luca, C
    JOURNAL OF CARDIOVASCULAR DIAGNOSIS AND PROCEDURES, 1997, 14 (04): : 191 - 201
  • [48] MECHANISM-BASED PK-PD MODELING FOR PREDICTION OF EFFICACY-SAFETY
    Danhof, Meindert
    DRUG METABOLISM REVIEWS, 2007, 39 : 33 - 33
  • [49] SUCCESSES, CHALLENGES AND FUTURE OF PK-PD MODELING IN DRUG DISCOVERY AND TRANSLATIONAL RESEARCH
    Chimalakonda, Anjaneya P.
    Garg, Amit
    DRUG METABOLISM REVIEWS, 2012, 44 : 6 - 6
  • [50] Dalbavancin plasma concentrations in 133 patients: A PK-PD observational study
    Hervochon, C.
    Hennart, B.
    Leroy, A. G.
    Corvec, S.
    Boutoille, D.
    Senneville, E.
    Sotto, A.
    Illes, G.
    Chavanet, P.
    Dubee, V.
    Bleibtreu, A.
    De Carne, M. C.
    Talarmin, J. P.
    Revest, M.
    Castan, B.
    Bellouard, R.
    Dailly, E.
    Allorge, D.
    Dinh, A.
    Lemaitre, F.
    Goirand, F.
    Le Turnier, P.
    Gregoire, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 59 - 59
12345